

PUBLISHED ON 08 DECEMBER 2022 (16:08 AEDT) | BY EUROZ HARTLEYS

# FDA NEW DRUG APPLICATION (NDA) FORMALLY UNDER REVIEW

BOT.ASX | BOTANIX PHARMACEUTICALS LIMITED | HEALTHCARE

PRICE  
A\$ 0.06TARGET PRICE  
A\$ 0.27  
(FROM A\$ 0.27)RECOMMENDATION  
**SPECULATIVE BUY**  
(FROM SPECULATIVE BUY)

ANALYST

**SETH LIZEE**

SLIZEE@EUROZHARTLEYS.COM

## Event

BOT has successfully received confirmation from the FDA that the Sofpironium Bromide New Drug Application (NDA) is now formally under review.

## Impact

This FDA communication initiates the formal review process, and follows BOT's earlier September NDA submission. The FDA confirmed there were no filing review issues identified and that the NDA was sufficiently complete to permit substantive review.

The FDA has granted Sofpironium Bromide a standard review (as expected), approval for the product remains on track for 3Q CY23.

Additionally, the FDA confirmed they do not believe that an advisory committee meeting is required, we indicatively view this as a positive, considering advisory committees are sometimes convened to assist in the review of complex applications or when opinions of independent experts/public is viewed as important to the FDA decision making process.

In the meantime, we can expect a mid-cycle review in 1Q CY23, which will provide further feedback on the progress of the FDA review.

Overall, we view this is as yet another milestone met, bringing BOT one step closer to potential FDA approval, and in time commercialisation.

Furthermore, as previously announced, the receipt of a positive day-74 letter triggers a US\$2m milestone payment to Fresh Tracks Therapeutics (formerly Brickell Biotech).

## Action

### Speculative Buy, \$0.27 Price Target

BOT remains very cheap and continues to trade at a significant discount to peers, this is despite the company making solid progress with its lead asset Sofpironium Bromide amongst other recent positive news.

Our analysis suggests BOT may be the cheapest ASX-listed company to have filed for an NDA (on its first asset) with the FDA (Figure 1).

Furthermore, companies undertaking an FDA review on their first drug have typically re-rated through the process, re-rating an average +60% by the day-74 response per our analysis, whereas BOT has traded sideways over this same timeframe (Figure 2).

We believe Sofpironium Bromide could potentially do +A\$130m of sales in the USA within its first year based on the number of prescriptions the drug is currently doing through its partner in Japan, a country which has a population nearly a third the size of the USA.

Management is in a solid position to execute, with the highly experienced team having previously developed, secured FDA approval for, and commercialised +30 products.

In our view, the takeaway from all of this is that there is significant upside to the current share price if BOT is even modestly successful.

## Catalyst

- Mid-cycle review – 1Q CY23
- FDA Approval – 3Q CY23

Share Price	0.06	A\$/sh
Price Target	0.27	A\$/sh
Valuation	0.27	A\$/sh
Shares on issue	1,283	m, Dil
Market Capitalisation	77.0	A\$m
Enterprise Value	53.8	A\$m
Debt (Pro-forma)	0.0	A\$m
Cash (Pro-forma)	15.4	A\$m
Unpaid cap	7.8	A\$m

## Directors & Management

Vince Ippolito	Chair
Matthew Callahan	ED
Dr William Bosch	ED
Dr Stewart Washer	ED
Danny Sharp	NED
Howie Mckibbon	COO
Dr Patricia Walker	CMO
Anthony Robinson	VP
Dr Jack Hoblitzell	SVP
Dr Ira Lawrence	Adv.
Dr Clarence Young	Adv.
Lynda Berne	Adv.

## Performance



Source: IRESS

## Analysis - Cheapest NDA Filing on ASX?

- We have attempted to explore what the market has paid for companies in this position in the past (specifically, companies securing approval on their first drug)
- In our analysis, we found 7 ASX listed companies that have previously (or are in the process) secured an FDA approval, as shown below (Figure 1):

Figure 1: Peer comparables


Ticker	Company	Product <sup>1</sup>	Approval Date	Market Cap (A\$m) <sup>2</sup>		%change
				NDA-filling	FDA Approval	
ACR	Acrux	Evamist®	31-Jul-07	113	260	130%
PXS	Pharmaxis	Aridol®	6-Oct-10	260	561	116%
CUV	Clinuvel	SCENESSE®	9-Oct-19	593	2,232	276%
TLX	Telix	Illucix®	20-Dec-21	491	2,460	401%
NEU	Neuren	Trofinetide	n/a <sup>3</sup>	521	n/a <sup>3</sup>	n/a <sup>3</sup>
<sup>1</sup> First approved product			Average	396	1,378	231%
<sup>2</sup> Fully diluted			Min	113	260	
<sup>3</sup> Not Yet approved (currently under review)			Max	593	2,460	

Source: EHL analysis, company announcements, IRESS

[note: excludes CSL (diversified business) & MYX (first drug approved before listed)]

- Whilst these companies are in varying positions (different disease areas, some with licensing agreements already in place, ex. US approvals, and/or multiple other products) – indicatively, the market has paid ~A\$110-600 million on FDA NDA filing day (pre- FDA approval) and ~A\$250-2,500 million upon FDA approval.
- BOT trades well below every single comp listed above with a fully diluted \$77 million market cap, which per our analysis would make it one of the cheapest ASX companies seeking FDA approval on their first drug
- Taking this analysis a step further, we can see these same companies have on average seen a progressive re-rate through the FDA review process, whereas BOT has traded sideways over this same time period (Figure 2).

Figure 2: Peer comparables, share price performance



Source: EHL analysis, company announcements, IRESS

- The company in our view has been priced to failure, this is in spite of various recent achievements, and the backing of a highly experienced management team who have previously developed, secured FDA approval for, and commercialised over 30 dermatology products.
- The takeaway from all of this is that there is significant upside to be captured if BOT is even modestly successful.

## Personal disclosures

We hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities, and we are not in possession of, nor does this Research contain any inside information.

No part of our compensation was, is or will be directly or indirectly, related to the specific recommendations or views expressed by the authoring analyst in this research, nor has any attempt been made to influence this Research.

## Company disclosures

The companies and securities mentioned in this report, include:

Botanix Pharmaceuticals Limited (BOT.ASX) | Price A\$0.06 | Target price A\$0.27 | Recommendation Speculative Buy;

*Price, target price and rating as at 08 December 2022 (\* not covered)*

## Additional disclosures

The analyst declares that they have a beneficial interest in: Botanix Pharmaceuticals Limited (BOT.ASX)

Euroz Hartleys declares that it has acted as underwriter to, and/or arranged an equity issue in, and/or been engaged in a capital raising during the last year. Euroz Hartleys has received a fee for these services from: Botanix Pharmaceuticals Limited (BOT.ASX)

Euroz Hartleys has received an allocation of shares and/or options as part of our fee for the provision of Corporate services. These holdings are maintained in our Nominee company, and may present a potential benefit to Euroz Hartleys when sold for: Botanix Pharmaceuticals Limited (BOT.ASX)

This report was prepared solely by Euroz Hartleys Limited. ASX Limited ABN 98 009 642 691 and its related bodies corporate ("ASX") did not prepare any part of the report and has not contributed in any way to its content. The role of ASX in relation to the preparation of the research reports is limited to funding their preparation, by Euroz Hartleys Limited in accordance with the ASX Equity Research Scheme. ASX does not provide financial product advice. The views expressed in this research report may not necessarily reflect the views of ASX. To the maximum extent permitted by law, no representation, warranty or undertaking, express or implied, is made and no responsibility or liability is accepted by ASX as to the adequacy, accuracy, completeness or reasonableness of the research reports for: Botanix Pharmaceuticals Limited (BOT.ASX)

## Other disclosures, disclaimers and certificates

### Copyright & Distribution

The material contained in this communication (and all attachments) is prepared for the exclusive use of clients of Euroz Hartleys Limited (ACN 104 195 057) only.

Euroz Hartleys Limited is the holder of an Australian Financial Services Licence (AFSL 230052) and is a participant of the Australian Securities Exchange Group.

The information contained herein is confidential. If you are not the intended recipient no confidentiality is lost by your receipt of it. Please delete and destroy all copies, and contact Euroz Hartleys Limited on (+618) 9488 1400. You should not use, copy, disclose or distribute this information without the express written authority of Euroz Hartleys Limited.

### Disclaimer & Disclosure

Euroz Hartleys Limited, and their associates declare that they deal in securities as part of their securities business and consequently may have an interest in the securities recommended herein (if any). This may include providing equity capital market services to the issuing company, hold a position in the securities, trading as principal or agent and as such may effect transactions not consistent with the recommendation (if any) in this report.

You should not act on any recommendation issued by Euroz Hartleys Limited without first consulting your investment adviser in order to ascertain whether the recommendation (if any) is appropriate, having regard to your objectives, financial situation and needs. Nothing in this report shall be construed as a solicitation to buy or sell a security, or to engage in or refrain from engaging in any transaction.

Euroz Hartleys Limited believes that the information and advice contained herein is correct at the time of compilation, however we make no representation or warranty that it is accurate, complete, reliable or up to date, nor do we accept any obligation to correct or update the opinions in it. The opinions expressed are subject to change without notice. No member of Euroz Hartleys Limited accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this material.

We cannot guarantee that the integrity of this communication has been maintained, is free from errors, virus interception or interference. The author of this publication, Euroz Hartleys Limited, its directors and their associates from time to time may hold shares in the security/securities mentioned in this Research document and therefore may benefit from any increase in the price of those securities. Euroz Hartleys Limited, and its Advisers may earn brokerage, fees, commissions, other benefits or advantages as a result of transactions arising from any advice mentioned in publications to clients.

To view the Euroz Hartleys' Quick Comment Disclaimers, please visit the below links:

<https://www.eurozhartleys.com/wp-content/uploads/December-Resources-Disclaimers.pdf>

<https://www.eurozhartleys.com/wp-content/uploads/December-Industrials-Disclaimers.pdf>